CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Canada

2017-07-05
Price :
Published : Jul-2017
No. of Pages : 228

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Canada

Summary

Canada is a mature healthcare market, with a strong focus on pharma R&D and a high level of total healthcare expenditure that is 11% of its Gross Domestic Product (GDP). The increasing elderly population and its associated disease burden are expected to drive the growth of the pharmaceutical market, while government initiatives to reduce healthcare expenditure may limit growth. The value of the Canadian pharmaceutical market increased from US$19.6 Billion in 2009 to US$22.6 Billion in 2016, at a Compound Annual Growth Rate (CAGR) of 2%. The market value is expected to reach US$25 Billion in 2021.

In 2016, the value of the generic pharmaceutical market was US$6.16 Billion. In 2016, generic drugs accounted for 70.2% of prescriptions in Canada, compared with 89% in the US. However, generic drug sales account for only 22.4% of the US$25.1 Billion pharmaceutical market. The use of generic medicines saved nearly US$20 Billion for the government in 2016. The generics market is expected to continue to grow as the government promotes generics usage and as quality perception improves among patients.

In 2016 healthcare expenditure in Canada stood at US$228.1 Billion, an increase of US$44.8 Billion from 2015. In 2009, the healthcare expenditure as a percentage of GDP was 11.6%, which decreased to an estimated 11.1% in 2016. In 2009, health expenditure per capita was approximately US$4,497, which increased to an estimated US$6,299 in 2016. The increasingly elderly population and associated disease burden have been driving the growth of the pharmaceutical market. In 2016, the elderly population accounted for 17% of the total population, and this is expected to increase at a CAGR of 3.7% to 20% by 2021.

Canadian medical device market was valued at US$8.6 Billion in 2009, which increased to US$10.5 Billion in 2016, and it is expected to grow at a CAGR of 4.2% from US$11.4 Billion in 2017 to US$13.4 Billion in 2021. The main segments were ophthalmic devices, orthopedic devices, drug delivery devices, in vitro diagnostics and healthcare IT.

The report “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Canada” is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Canada.

In particular, this report provides the following analysis –
– Provides an overview of the Canadian healthcare market and its key driving factors. It also gives a snapshot of the demographic, regulatory, and reimbursement landscape and healthcare infrastructure in Canada.
– Provides an overview of the Canadian pharmaceutical and medical device markets, covering market size; the market shares of generic, Over-the-Counter (OTC) and biologic/biosimilar products; and the key drivers and barriers for the overall market. It also includes profiles of the major players, as well as SWOT assessments.
– Covers the reimbursement and payer landscape, and includes details of the reimbursement process, insurance providers, pricing policies and drug price trends in Canada.
– Provides detailed analysis of the political and economic environment in Canada, and analyses economic indicators, demographics, and healthcare infrastructure and expenditure.
– Provides an overview of the opportunities for and challenges to growth in the Canadian healthcare market.

Companies mentioned in this report: Johnson & Johnson, Novartis, Teva, Apotex, Gilead.

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in Canada, and includes –
– An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
– Profiles and SWOT analyses of the major players in the pharmaceutical market (Johnson & Johnson, Novartis, Teva, Apotex and Gilead) and profiles and SWOT analyses of the major players in the medical device market (Johnson & Johnson, Medtronic, Baxter, Fresenius and Sonova)
– An insightful review of the reimbursement and regulatory landscape, of which analysis includes details of the healthcare reimbursement process, the regulatory agencies and the approval processes for new drugs and medical devices
– Detailed analysis of the political and economic environment, covering economic indicators, demographics, healthcare infrastructure and healthcare expenditure
– An overview of the opportunities for and challenges to growth in the Canadian healthcare market

Reasons to buy

This report will enhance your decision-making capability by allowing you to –
– Develop business strategies by understanding the trends shaping and driving the Canadian healthcare market
– Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to impact the healthcare market in the future
– Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors
– Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment, and strategic partnership
– Identify, understand, and capitalize on the opportunities and challenges in the Canadian healthcare market

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
Publisher : GlobalData
More Reports
Title Price Buy Now

Digital Pathology Market by Product (Artificial Intelligence, Scanner, Software, Storage), Type (Human, Veterinary), Application (Teleconsultation, Disease Diagnosis, Drug Discovery), End-User (Pharmaceutical Companies, Hospitals) – Global Forecast to 2025

“The digital pathology market is projected to grow at a CAGR of 13.8% during the forecast period (2020–2025).” The global digital pathology market is projected to reach USD 1,054 million by 2025 from USD 553 million in 2020, at a CAGR of 13.8% during the forecast period. The key factors driving the growth of this market include the increasing adoption of digital pathology to enhance lab efficiency, rising prevalence of cancer, growing application of digital pathology in drug development & companion diagnostics, and increasing initiatives by industry players. However, the high cost of digital pathology systems is expected to restrict market growth to a certain extent. “Adoption of artificial intelligence is expected to increase during the forecast period.” The adop......
$4950

Pharmaceutical Packaging Equipment Market by Product (Aseptic Packaging, Blister, Strip, Bottle, Tube, Carton, Case Packer, Wrapping Machine, Palletizing, Labeling & Serialization), Type (Tablet, Powder, Cream, Syrup, Aerosol), Region – Global Forecast to 2025

The pharmaceutical packaging equipment market is expected to grow at a CAGR of 7.4% in the forecast period. The global pharmaceutical packaging equipment market size is projected to reach USD 10.4 billion by 2025 from USD 7.3 billion in 2020, at a CAGR of 7.4% from 2020 to 2025. The growth of the market is driven by the rapidly growing generic & biopharmaceutical markets, growth in OTC drug sales, rising need for flexible & integrated packaging equipment, increased offshore manufacturing in the pharmaceuticals market, and the introduction of regulatory standards on packaging & stringent norms against counterfeiting. However, factors such as the adoption of refurbished packaging equipment and the high cost of packaging equipment are expected to restrain market growth to a cer......
$4950

Meningococcal Vaccines – Global Drug Forecast and Market Analysis to 2029

Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2029 Summary Meningococcal disease is an infection caused by Neisseria meningitidis bacteria, and, although relatively rare, is widely feared because of its high mortality rate even in otherwise healthy individuals. Serogroups A, B, C, W, and Y are the most common meningococcal types in the nine major markets (9MM) covered in this report (US, France, Germany, Italy, Spain, UK, Argentina, Brazil, and China), and immunization of high-risk groups such as infants and adolescents provides the best protection against the infection. Immunization with conjugated meningococcal serogroup C (MenC) is routinely recommended for infants in the 5EU and Brazil, and immunization against serogroup ACWY (MenACWY vaccines) is recommended i......
$10995

Invasive Meningococcal Disease – Epidemiology Forecast to 2029

Invasive Meningococcal Disease - Epidemiology Forecast to 2029 Summary Invasive meningococcal disease (IMD) is a life-threatening condition caused by the bacterium Neisseria meningitidis (N. meningitidis). N. meningitidis is an encapsulated gram-negative bacterium that exists without complication in roughly 5-11% of adults and up to 25% of adolescents. However, if the bacterium moves beyond the nasopharynx and invades body tissue, serious illness can arise, usually in the form of meningitis or septicemia. Symptoms of disease can include fever, headache, stiff neck, nausea, photophobia, and fatigue, among others. The bacterium is spread by respiratory droplets through close or prolonged contact with an infected person and is not as contagious as the common cold or flu. In 2019, there wer......
$3995

Ulcerative Colitis – Epidemiology Forecast to 2029

Ulcerative Colitis - Epidemiology Forecast to 2029 Summary Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by chronic inflammation of the large intestine and the rectum. The inflammation occurs only in the innermost layer of the lining of the intestine. In UC, ulcers develop on the surface of the bowel lining; these may bleed and produce mucus. If the inflammation is confined to rectum, it is called proctitis (Crohn's and Colitis Foundation of America, 2014; Crohn's and Colitis UK, 2019). UC can occur at any age, though most people are diagnosed in their mid-thirties. Men and women are equally likely to be affected, but older men are more likely to be diagnosed than older women. GlobalData epidemiologists utilized historical data obtained from peer-reviewed......
$3995

Contract Dose Manufacturing Industry by the Numbers – Composition, Size, Market Share and Outlook – 2020 Edition

Contract Dose Manufacturing Industry by the Numbers - Composition, Size, Market Share and Outlook - 2020 Edition Summary This expert trend report is a comprehensive look at the finished dose contract manufacturing landscape in 2020, including analysis of dose CMO M&A activity, market size and share. It is a critical source for strategic planning efforts and will improve understanding of crucial components of the supply chain that will provide insights for supplier selection and management. This report gives an important expert quantitative analysis on the contract dose manufacturing industry. Findings are based on the industry's most comprehensive database of the dose CMO industry (GlobalData's Pharma Intelligence Center Contract Service Providers Database) this analysis is driven by a ......
$4995

Egypt Healthcare, Regulatory and Reimbursement Landscape – CountryFocus

Egypt Healthcare, Regulatory and Reimbursement Landscape - CountryFocus Summary GlobalData, the industry analysis specialist, has released its latest report, "Egypt Healthcare, Regulatory and Reimbursement Landscape - CountryFocus". The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in Egypt. It identifies the key trends in the country's healthcare market and provides insights into its demographic, regulatory and reimbursement landscape, and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalDa......
$1995

Coronavirus Disease 2019 (COVID-19) Impact on Telemedicine, a Physician Perspective

Coronavirus Disease 2019 (COVID-19) Impact on Telemedicine, a Physician Perspective Summary Telemedicine is the use of electronic communication for the delivery of remote clinical care. It has been recognized as a critical strategy during the ongoing coronavirus disease 2019 (COVID-19) pandemic to limit the risk of person-to-person transmission of the virus as social distancing has become the norm. It is widely anticipated that COVID-19 may be the tipping point for telemedicine as the full potential of the technology is increasingly realized by patients, healthcare systems, and payers. As a result of the pandemic, regulations and policies governing reimbursement and use of telemedicine have changed significantly, leading to expanded access and an unprecedented demand for these services.......
$1495

Greece Healthcare, Regulatory and Reimbursement Landscape – CountryFocus

Greece Healthcare, Regulatory and Reimbursement Landscape - CountryFocus Summary GlobalData, the industry analysis specialist, has released its latest report: "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Greece". The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in Greece. It identifies the key trends in the country's healthcare market and provides insights into its demographic, regulatory and reimbursement landscape, and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis by Glob......
$1995

Hypoglycemia Disease – Global Clinical Trials Review, H2, 2020

Hypoglycemia Disease - Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Hypoglycemia Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Hypoglycemia Clinical trials scenario. This report provides top line data relating to the clinical trials on Hypoglycemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinical trials databas......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy